Welcome to our dedicated page for Laboratory Corporation of America Holdings news (Ticker: $LH), a resource for investors and traders seeking the latest updates and insights on Laboratory Corporation of America Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Laboratory Corporation of America Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Laboratory Corporation of America Holdings's position in the market.
Labcorp (LH) will be webcasting its Annual Meeting of Shareholders on May 14 at 9:00 a.m. ET. The webcast can be viewed on Labcorp's Investor Relations website, with an archived replay available for one year.
Labcorp (NYSE: LH) has received court approval to acquire assets of Invitae (OTC:NVTAQ), a leading medical genetics company, for $239 million in cash and non-cash consideration. The acquisition will advance Labcorp's specialty testing strategy in areas like oncology and rare diseases. The transaction is expected to enhance patient care, provide insights into health, and support clinical trials and treatment regimens.
Geneoscopy, Inc. announces FDA approval for its noninvasive colorectal cancer screening test, ColoSense, with 93% sensitivity for detecting colorectal cancer and 45% sensitivity for detecting advanced adenomas in average-risk individuals. The breakthrough device provides a dynamic view of disease activity using RNA biomarkers, offering a promising tool for early-age onset CRC detection. The study showed 100% sensitivity for CRC in the 45-49 age group, a critical demographic, with a commercial launch planned in collaboration with Labcorp.
Labcorp has received FDA approval for the first companion diagnostic for use with Pfizer's newly approved gene therapy to treat patients with Hemophilia B. The nAbCyte Anti-AAVRh74var HB-FE Assay will determine patient eligibility for treatment with BEQVEZ, Pfizer's gene therapy. Approximately 6,000 individuals in the US have Hemophilia B, and up to 60% of the population may have preexisting anti-AAV antibodies. Labcorp's assay will help identify patients suitable for gene therapy, marking a significant advancement in precision medicine and gene therapy.